N-methyl-2-[6-(pyrazin-2-ylamino)-2-pyridin-3-ylpyrimidin-4-yl]-2-azaspiro[4.5]decane-7-carboxamide
C24H28N8O — CID 166061302
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-methyl-2-[6-(pyrazin-2-ylamino)-2-pyridin-3-ylpyrimidin-4-yl]-2-azaspiro[4.5]decane-7-carboxamide
N-methyl-2-[6-(pyrazin-2-ylamino)-2-pyridin-3-ylpyrimidin-4-yl]-2-azaspiro[4.5]decane-7-carboxamide (PubChem CID 166061302) has the molecular formula C24H28N8O and a molecular weight of 444.54 g/mol. Its IUPAC name is N-methyl-2-[6-(pyrazin-2-ylamino)-2-pyridin-3-ylpyrimidin-4-yl]-2-azaspiro[4.5]decane-7-carboxamide.
Molecular Properties
| Compound Name | N-methyl-2-[6-(pyrazin-2-ylamino)-2-pyridin-3-ylpyrimidin-4-yl]-2-azaspiro[4.5]decane-7-carboxamide |
|---|---|
| PubChem CID | 166061302 |
| Molecular Formula | C24H28N8O |
| Molecular Weight | 444.54 g/mol |
| Exact Mass | 444.24 |
| IUPAC Name | N-methyl-2-[6-(pyrazin-2-ylamino)-2-pyridin-3-ylpyrimidin-4-yl]-2-azaspiro[4.5]decane-7-carboxamide |
| SMILES | CNC(=O)C1CCCC2(CCN(c3cc(Nc4cnccn4)nc(-c4cccnc4)n3)C2)C1 |
| InChI | InChI=1S/C24H28N8O/c1-25-23(33)17-4-2-6-24(13-17)7-11-32(16-24)21-12-19(29-20-15-27-9-10-28-20)30-22(31-21)18-5-3-8-26-14-18/h3,5,8-10,12,14-15,17H,2,4,6-7,11,13,16H2,1H3,(H,25,33)(H,28,29,30,31) |
| InChIKey | ZHRNMMBWQCFTPB-UHFFFAOYSA-N |
| XLogP | 3.20 |
| TPSA | 108.82 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 444.54 |
| LogP ≤ 5 | 3.20 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 166061302 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.